Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
03.01. | CNS Pharmaceuticals, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
CNS PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
11.12.24 | CNS Pharmaceuticals, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
05.12.24 | CNS Pharmaceuticals sets date for virtual investor event | 2 | Investing.com | ||
05.12.24 | CNS Pharmaceuticals veranstaltet am 11. Dezember 2024 den "Virtual Analyst & Investor Day" | 228 | IR-WORLD | Live-Webcast-Diskussion mit international anerkannten Meinungsbildnern auf dem Gebiet von Glioblastoma Multiforme
(GBM)
Das Unternehmen widmet sich mit großem Engagement der aggressivsten... ► Artikel lesen | |
05.12.24 | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024 | 237 | ACCESS Newswire | Live webcast discussion featuring internationally renowned Glioblastoma Multiforme (GBM) Key Opinion LeadersCompany committed to addressing the most aggressive type of brain cancer with an average survival... ► Artikel lesen | |
03.12.24 | CNS Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
25.11.24 | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM After Failure of Standard First Line Therapy | 301 | ACCESS Newswire | Poster presented at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)Primary analysis data in potentially pivotal GBM study with lead program, Berubicin, on track for the first half... ► Artikel lesen | |
18.11.24 | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology | 160 | ACCESS Newswire | HOUSTON, TX / ACCESSWIRE / November 18, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary... ► Artikel lesen | |
15.11.24 | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results | 267 | ACCESS Newswire | Primary analysis data in potentially pivotal GBM study with lead program, Berubicin, on track for the first half of 2025Company strengthens cash position to extend runway to fund operations beyond data... ► Artikel lesen | |
14.11.24 | CNS Pharmaceuticals, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
04.11.24 | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment | 344 | ACCESS Newswire | Segment featuring leading Neuro-Oncologist and Glioblastoma Key Opinion Leader, Professor Michael WellerAccess the segment here HOUSTON, TX / ACCESSWIRE / November 4, 2024 / CNS Pharmaceuticals, Inc.... ► Artikel lesen | |
01.11.24 | CNS Pharmaceuticals erhält Fristverlängerung für Nasdaq-Compliance | 3 | Investing.com Deutsch | ||
01.11.24 | CNS Pharmaceuticals granted Nasdaq compliance extension | 1 | Investing.com | ||
01.11.24 | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement | 241 | ACCESS Newswire | HOUSTON, TX / ACCESSWIRE / November 1, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary... ► Artikel lesen | |
01.11.24 | CNS Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
23.10.24 | CNS Pharmaceuticals secures $3 million in registered direct offering | 8 | Investing.com | ||
23.10.24 | CNS Pharmaceuticals sichert sich 3 Millionen US-Dollar durch registrierte Direktplatzierung | 2 | Investing.com Deutsch | ||
23.10.24 | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules | 348 | ACCESS Newswire | HOUSTON, TX / ACCESSWIRE / October 23, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary... ► Artikel lesen | |
23.10.24 | CNS Pharmaceuticals droht Delisting von der NASDAQ aufgrund von Preisregel | 5 | Investing.com Deutsch | ||
23.10.24 | CNS Pharmaceuticals faces NASDAQ delisting over price rule | 3 | Investing.com |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
CUREVAC | 3,922 | -1,01 % | CureVac Aktie: BRUTALE PROGNOSE zwingt Anleger zum Handeln. So sollten Sie HEUTE reagieren! | ||
CORE ONE LABS | 0,079 | 0,00 % | Prusa gibt Update zum 3D-Drucker CORE One: Erste Auslieferungen stehen bevor | ||
TEMPUS AI | 47,590 | 0,00 % | Tempus AI: KI-App 'olivia' und Pelosis Investition treiben Aktienkurs | ||
IMMUNOVANT | 23,590 | 0,00 % | Immunovant, Inc. (IMVT): The Biotech Stock with Biggest Upside Potential | ||
SUMMIT THERAPEUTICS | 22,100 | 0,00 % | Why Summit Therapeutics Stock Is Jumping Today | ||
APOGEE THERAPEUTICS | 39,460 | 0,00 % | Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions | Interim safety and pharmacokinetic data from Phase 1 healthy volunteers trial anticipated in 2H 2025 APG777 + APG333 can potentially address key drivers of respiratory diseases more broadly versus... ► Artikel lesen | |
VERA THERAPEUTICS | 33,700 | 0,00 % | Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on January 8, 2025, the Compensation Committee granted inducement awards consisting... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 6,880 | 0,00 % | Recursion Pharmaceuticals, Inc. (RXRX): Revolutionizing Drug Discovery with AI and Strategic Collaborations for Strong Growth | ||
QIAGEN | 45,910 | +0,70 % | Qiagen schüttet clever aus | Bei Qiagen profitieren Anleger nicht nur von verbesserten fundamentalen Aussichten: Das Unternehmen schüttet erneut Kapital über einen Reverse Stock Split aus - insgesamt 300 Mio. US-Dollar. Die Venloer... ► Artikel lesen | |
ADMA BIOLOGICS | 16,200 | 0,00 % | EWTX Yields Over 300% Returns, ADMA Records 200% Gains - Did You Strike While The Iron Is Hot? | WASHINGTON (dpa-AFX) - Biotech investing is a high-stakes game that may not suit the faint-hearted due to its inherent volatility. However, this sector can offer astronomical returns when investors... ► Artikel lesen | |
HARMONY BIOSCIENCES | 40,420 | 0,00 % | Harmony Biosciences (NASDAQ:HRMY) Earns Buy Rating from HC Wainwright | ||
EVOTEC | 7,940 | +0,57 % | MIDDAY BRIEFING - Unternehmen und Märkte: MUNICH RE, BERTELSMANN, BORUSSIA DORTMUND, EASYJET, EVOTEC, OLDENBURGISHCHE LANDESBANK, TUIFLY, VOSSLOH | DJ MIDDAY BRIEFING - Unternehmen und Märkte
Der Markt-Überblick am Mittag, zusammengestellt von Dow Jones Newswires:
+++++ AKTIEN- UND ANLEIHEMÄRKTE (13:06 Uhr) +++++
INDEX ... ► Artikel lesen | |
QUANTUM-SI | 2,440 | 0,00 % | Quantum-Si Incorporated: Quantum-Si Showcases Advances in Multiomics at the Festival of Genomics UK | Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company, announces its participation in the upcoming Festival of Genomics UK, taking place on... ► Artikel lesen | |
BIONTECH | 111,30 | -1,15 % | BioNTech-Aktie: Wird 2025 ein gutes Jahr? | Im vergangenen Jahr hat die BioNTech-Aktie nicht gerade mit einer starken Performance geglänzt. Worauf müssen sich Anleger 2025 einstellen? Was spricht für steigende Kurse, was dagegen? Verhaltener... ► Artikel lesen | |
JANUX THERAPEUTICS | 40,840 | 0,00 % | Pre-market Movers: Cheetah Net Supply Chain Service, NLS Pharmaceutics, PSQ Holdings, Janux Therapeutics, Coherus BioSciences | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.45 A.M. ET).In the Green Cheetah Net Supply Chain Service Inc. (CTNT) is up... ► Artikel lesen |